{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:13:17Z","timestamp":1767928397763,"version":"3.49.0"},"reference-count":31,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,4,22]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>A 7-year-old girl without a significant previous medical history was diagnosed with X-linked hypophosphatemic rickets (XLHR) due to a rare, most likely pathogenic, <jats:italic>PHEX<\/jats:italic> gene variant after a 4-year delayed diagnosis due to mild clinical presentation. At 2 years of age, her intoeing and femoral bowing were attributed to physiologic bowing and borderline vitamin D sufficiency, despite phosphorus not being measured. Hypophosphatemia was eventually detected after incomplete improvement of bowing and leg length discrepancy with suboptimal linear growth. This rare <jats:italic>PHEX<\/jats:italic> variant (c.1949T&gt;C, p.Leu650Pro) further supported the clinical diagnosis of XLHR. Treatment with burosumab (an anti-FGF23 monoclonal antibody) normalised phosphorus and alkaline phosphatase levels and improved her bowing. The diverse phenotypic presentation of this variant can result in delayed diagnosis and highlights the importance of prompt assessment of phosphorus levels in patients with skeletal deformities to ensure timely recognition and treatment.<\/jats:p>","DOI":"10.1136\/bcr-2020-240336","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:46:07Z","timestamp":1621431967000},"page":"e240336","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Rare <i>PHEX<\/i> variant with insidious presentation leads to a delayed diagnosis of X-linked hypophosphatemia"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-257X","authenticated-orcid":false,"given":"Cathrine","family":"Constantacos","sequence":"first","affiliation":[{"name":"Pediatrics, Section of Endocrinology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janel Darcy","family":"Hunter","sequence":"additional","affiliation":[{"name":"Pediatrics, Section of Endocrinology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Tharpe","family":"Walsh","sequence":"additional","affiliation":[{"name":"Pediatrics, Section of Endocrinology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3204-4142","authenticated-orcid":false,"given":"Andrew Michael","family":"South","sequence":"additional","affiliation":[{"name":"Pediatrics, Section of Nephrology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA"},{"name":"Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"2025082711273375000_14.5.e240336.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.10.018"},{"key":"2025082711273375000_14.5.e240336.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.121"},{"key":"2025082711273375000_14.5.e240336.3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025082711273375000_14.5.e240336.4","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22932"},{"key":"2025082711273375000_14.5.e240336.5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.6065\/apem.2020.25.1.63","article-title":"Identification of a novel variant in the PHEX gene using targeted gene panel sequencing in a 24-month-old boy with hypophosphatemic rickets","volume":"25","author":"Jo","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2025082711273375000_14.5.e240336.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.03.009","article-title":"Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)","volume":"103S","author":"Rothenbuhler","year":"2020","journal-title":"Metabolism"},{"key":"2025082711273375000_14.5.e240336.7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00338","article-title":"Clinical evidence for the benefits of burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children","volume":"11","author":"Schindeler","year":"2020","journal-title":"Front Endocrinol"},{"key":"2025082711273375000_14.5.e240336.8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked Hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025082711273375000_14.5.e240336.9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"2025082711273375000_14.5.e240336.10","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked Hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"2025082711273375000_14.5.e240336.11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"2025082711273375000_14.5.e240336.12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025082711273375000_14.5.e240336.13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15201218"},{"key":"2025082711273375000_14.5.e240336.14","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e328334a600"},{"key":"2025082711273375000_14.5.e240336.15","first-page":"266","article-title":"Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the prevention of renal and vascular endstage disease (PREVEND) study","volume":"3","author":"De Jong","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025082711273375000_14.5.e240336.16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-211961","article-title":"Chiari malformation, syringomyelia and bulbar palsy in X linked hypophosphataemia","volume":"2015","author":"Watts","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025082711273375000_14.5.e240336.17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00467-019-04290-y","article-title":"Mineralized tissues in hypophosphatemic rickets","volume":"35","author":"Robinson","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"2025082711273375000_14.5.e240336.18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","article-title":"Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism","volume":"18","author":"Alon","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"2025082711273375000_14.5.e240336.19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1507\/endocrj.EJ16-0199","article-title":"Hypertension is a characteristic complication of X-linked hypophosphatemia","volume":"64","author":"Nakamura","year":"2017","journal-title":"Endocr J"},{"key":"2025082711273375000_14.5.e240336.20","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2016.1242604"},{"key":"2025082711273375000_14.5.e240336.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46122"},{"key":"2025082711273375000_14.5.e240336.22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.5650050508","article-title":"Normal left ventricular performance in children with X-linked hypophosphatemic rickets: a Doppler echocardiography study","volume":"5","author":"Vered","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2025082711273375000_14.5.e240336.23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2450"},{"key":"2025082711273375000_14.5.e240336.24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008480-200108000-00015","article-title":"Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets","volume":"13","author":"Moltz","year":"2001","journal-title":"Curr Opin Pediatr"},{"key":"2025082711273375000_14.5.e240336.25","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082711273375000_14.5.e240336.26","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340"},{"key":"2025082711273375000_14.5.e240336.27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","article-title":"Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets","volume":"33","author":"Meyerhoff","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2025082711273375000_14.5.e240336.28","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.108955"},{"key":"2025082711273375000_14.5.e240336.29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ghir.2017.08.001","article-title":"Two-Year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)","volume":"36","author":"Rothenbuhler","year":"2017","journal-title":"Growth Horm IGF Res"},{"key":"2025082711273375000_14.5.e240336.30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0399"},{"key":"2025082711273375000_14.5.e240336.31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.6.e593"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-240336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:27:40Z","timestamp":1756319260000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-240336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bcr-2020-240336"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-240336","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}